CD274 and non-small cell lung carcinoma: Pembrolizumab was shown to have significantly longer PS and OS and fewer adverse effects compared with platinum-based chemotherapy and so became a new standard of care for the first-line treatment of patients with ‘PD-L1 high’ NSCLC [22].